SWK — Investor Presentation (April 2021)
33 slides from SWK's investor presentation, Apr 2, 2021
Slide 1: Collaborative Approach to Life Science Financing
1 Collaborative Approach to Life Science Financing Shareholder Presentation March 31, 2021
Slide 2: Forward-looking and Cautionary Statements
2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $20mm financings, a market niche that is largely ignored by
Slide 4: SWK Holdings - Segments
4 SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Product acquisitions • Peptelligence ® and ProPerma Œ dosing technologies • CDMO services • 505b2 drug development SWK operates through two segments: Life Scienc
Slide 5: Life Science Finance Opportunity
5 Life Science Finance Opportunity Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/mid - sized life science cos - Few participants exist for sub - $20mm life science financings Life science products are highly portable - Approved & mar
Slide 6: Value Creation Strategy
6 Value Creation Strategy Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other equity - like upside features to enhance return profile Select
Slide 7: Book Value Components
7 Book Value Components Tangible Finance Book Value / Share = $15.84 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.81 • In August 2
Slide 8: Corporate Milestones
8 Corporate Milestones 2014 x $113mm raised through private placement and rights offering x Ended year with $93mm yielding assets 2015 x Winston Black named CEO x 1/10 effective reverse stock split x Ended year with $99mm yielding assets 2016 x Team rebuilt and investment process improved x Ended ye
Slide 9: Finance Segment Portfolio Overview: 4Q20
79% 19% 1% Portfolio Composition First Lien Royalty Warrants 9 Finance Segment Portfolio Overview: 4Q20 * Finance receivables and marketable investments; does not include new or repaid finance receivables closed post - quarter ** Includes public company warrants; private warrants carried at zero val
Slide 10: Financial Snapshot
$126.4 $152.0 $167.1 $175.1 $205.9 $100 $125 $150 $175 $200 $225 2016 2017 2018 2019 2020 Total Yielding Assets* ($ in millions; at end of period) $23.5 $22.4 $37.5 $26.0 $30.7 $36.7 $20 $22 $24 $26 $28 $30 $32 $34 $36 $38 $40 2015 2016 2017 2018 2019 2020 Total Revenue ($ in millions) $204.3 $208.0
Slide 11: Financing Strategy: Effective Yields
10.0% 12.5% 15.0% 17.5% $150.0 $160.0 $170.0 $180.0 $190.0 $200.0 $210.0 Yielding Portfolio and Weighted Effective Yield ($ in millions; at end of period) Yielding Portfolio* Effective Yield** 11 Financing Strategy SWK Targets Low - to - Mid Teens Effective Yields 4Q20 Finance Segment Effective Yiel
Slide 12: Realized Yield vs Effective Yield
10.0% 15.0% 20.0% 25.0% Realized Yield vs Effective Yield ($ in millions; at end of period) Effective Yield Realized Yield* 12 Financing Strategy SWK’s Portfolio Realized Yield Has Consistently Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio Realized Yield is i
Slide 13: Current Structured Credit Portfolio
13 Current Structured Credit Portfolio
Slide 14: Current Royalty Portfolio
14 Current Royalty Portfolio
Slide 15: Portfolio Realizations
15 Portfolio Realizations As of March 31, 2021, SWK has exited 19 financings for a total 1.3x CoC return and 20% weighted average IRR ̶ 16 resulted in positive realizations with a cumulative 1.4x CoC and weighted average 32% IRR ̶ SynCardia position was sold to distressed private equity firm with
Slide 16: Portfolio Realizations to Strategic Buyers
16 Portfolio Realizations to Strategic Buyers 12 realizations to strategic buyers demonstrated a median 30 % LTV of SWK’s original loan value Eight of the 11 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology $ in mm Target Buyer Clos
Slide 17: Sourcing
17 Sourcing SWK has a well - developed and diversified sourcing network SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $20mm financings Fr
Slide 18: Financing Structures
Financing Structures 18 Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commer
Slide 19: Value Proposition to Partners
19 Value Proposition to Partners Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive an
Slide 20: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 20 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne
Slide 21: Historical Financing: Galil Medical
Historical Financing: Galil Medical 21 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In
Slide 22: Enteris BioPharma Acquisition – A Transformational Opportunity
Enteris BioPharma Acquisition – A Transformational Opportunity 22 • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of milestones an
Slide 23: Enteris Corporate Overview: Commercial Platform
Commercial Platform 23 Enteris Corporate Overview Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typically injected, includin
Slide 24: Enteris: Cara Therapeutics and Oral KORSUVA
Enteris: Cara Therapeutics and Oral KORSUVA Œ 24 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris’ Peptelligence technology • Currently the subject of four late - stage clinical trials for pruritus • Phase 2 trial targeting pruritus in patients with CKD produced positive
Slide 25: Leadership Team
25 Leadership Team Winston Black Chief Executive Officer • Appointed CEO in 2016 • Co - founded PBS Capital Management • Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer • Appointed CFO in 2012 • Cu
Slide 26: SWK – Rapidly-Growing Life Science Focused Specialty Finance Company
26 SWK – Rapidly - Growing Life Science Focused Specialty Finance Company Custom financing solutions for commercial - stage healthcare companies and royalty owners Targeting $5mm to $20mm financings, a niche that is largely ignored by larger market participants Focus is secured financings and royalt
Slide 27: Balance Sheet
$ in 000s Dec-20 Dec-19 Dec-18 Dec-17 Dec-16 ASSETS Cash and cash equivalents 3,008$ 11,158$ 20,227$ 30,557$ 32,182$ Interest and accounts receivable, net 1,911 2,554 2,195 1,637 1,054 Marketable investments 1,210 1,802 - 1,856 2,621 Other current assets 542 1,087 138 126 240 Total current assets 6,
Slide 28: Income Statement
$ in 000s, except per share amounts Dec-20 Dec-19 Dec-18 Dec-17 Dec-16 Revenues Finance receivable interest income, including fees 30,800$ 30,117$ 25,978$ 26,877$ 15,747$ Pharmaceutical development 5,903 621 - - - Marketable investments interest income - - - - 92 Income related to investments in unc
Slide 29: Cash Flow Statement
$ in 000s,* Dec-20 Dec-19 Dec-18 Dec-17 Dec-16 Cash flows from operating activities: Consolidated net income $5,202 $23,828 $6,195 $8,251 $32,041 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entity - - - (10,530) (6,219)
Slide 30: Reconciliation of Non-GAAP Adjusted Net Income
30 Reconciliation of Non - GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - c
Slide 31: Reconciliation of Non-GAAP Specialty Finance Net Income
31 Reconciliation of Non - GAAP Specialty Finance Net Income The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods de
Slide 32: Contact Information
32 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Winston Black: ̶ Phone: 972.687.7251 ̶ Email: wblack@swkhold.com • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com • Office address: ̶ 14755 Preston Road, Ste 105 Dallas
Slide 33: Collaborative Approach to Life Science Financing
33 Collaborative Approach to Life Science Financing